Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
97.76
+2.95 (3.11%)
Nov 21, 2024, 1:28 PM EST - Market open

Blueprint Medicines Revenue

Blueprint Medicines had revenue of $128.18M in the quarter ending September 30, 2024, with 126.61% growth. This brings the company's revenue in the last twelve months to $434.42M, up 100.93% year-over-year. In the year 2023, Blueprint Medicines had annual revenue of $249.38M with 22.22% growth.

Revenue (ttm)
$434.42M
Revenue Growth
+100.93%
P/S Ratio
13.57
Revenue / Employee
$663,229
Employees
655
Market Cap
6.21B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023249.38M45.34M22.22%
Dec 31, 2022204.04M23.96M13.30%
Dec 31, 2021180.08M-613.66M-77.31%
Dec 31, 2020793.74M727.22M1,093.37%
Dec 31, 201966.51M21.99M49.39%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Elanco Animal Health 4.45B
R1 RCM 2.46B
RadNet 1.77B
Lantheus Holdings 1.50B
Merit Medical Systems 1.33B
Halozyme Therapeutics 947.36M
Corcept Therapeutics 628.56M
Cytokinetics 3.22M
Revenue Rankings